Korro is a net-cash-priced RNA-editing platform making a high-stakes GalNAc pivot—massive upside if translation works, severe downside if it doesn’t.
Overview
Korro Bio (KRRO) is a Cambridge-based clinical-stage genetic medicines company developing RNA-editing therapies via its OPERA® platform, which edits RNA transiently and reversibly rather than permanently altering DNA. OPERA uses synthetic oligonucleotides to recruit endogenous ADAR enzymes for precise A-to-I edits, enabling mutation repair or protein pathway modulation. The strategic focus is liver-targeted disease across rare genetic disorders and larger metabolic/hepatology indications, with lead areas in Alpha-1 Antitrypsin Deficiency (AATD) and hyperammonemia (UCD/HE) via KRRO-121. The company is pre-commercial; near-term revenue comes from collaborations, primarily Novo Nordisk (recognized $1.1M in Q3 2025), though the collaboration entered a 12-month hold starting Nov 2025. After KRRO-110 (LNP) produced human editing but insufficient AAT protein levels, Korro restructured (34% workforce reduction) and pivoted delivery to GalNAc, extending cash runway into H2 2027. With ~$102.5M cash (Sept 30, 2025) and an “option-like” valuation near net cash, the thesis hinges on upcoming GalNAc-AATD and KRRO-121 milestones to re-establish clinical credibility and unlock partnering/financing on better terms.